In Europe, treatment of high-risk NB patients with the chimeric anti-GD2 antibody (Ab) dinutuximab beta (DB) in combination with the immune stimulating cytokine interleukin-2 (IL-2) resulted in a 15% improvement in 5-year survival compared to the standard treatment [2]. This evidence concerns the gene IL2 and neuroblastoma.